CASE STUDY | MEDICAL COMMUNICATIONS
When the Right Experts Were Unclear, We Defined the KOL Landscape.
THE CHALLENGE
Fragmented Care Models Complicated KOL Selection
A pharmaceutical company preparing to launch a novel therapy in a rare neurological condition faced a significant challenge: aligning on which stakeholders to prioritize in a complex, multispecialty care landscape.
Care for the condition spanned dysautonomia and movement disorder specialists, with additional influence from adjacent disciplines. While the core stakeholder groups were known, there was limited clarity on each specialty’s role in diagnosis, treatment, ongoing management, and influence across the patient journey.
THE BREAKTHROUGH
Defining High-Value KOLs to Enable Targeted Engagement
BGBx identified that broad outreach was insufficient in a fragmented, multi-specialty landscape. The challenge was not just access to experts, but clarity on which stakeholders across each specialty were most relevant to drive engagement and support the launch.
Through our proprietary Breakthrough Process, powered by 3D Science, we refined and validated stakeholder relevance and prioritization before scaling engagement.
The approach integrated:
- Billions of data points across scientific, clinical, and digital sources to identify experts based on real-world influence
- Real-world claims data to assess clinical activity, patient volume, and referral patterns
- Digital listening and social intelligence to capture scientific discourse and emerging voices
- Tiered segmentation based on relevance and engagement opportunity
- Pre- and post-launch engagement planning aligned to stakeholder roles
This framework ensured the right experts were identified and engaged, improving focus and effectiveness across the treatment landscape.
THE RESULTS
Focused KOL Engagement Improved Launch Execution and Readiness
Our approach improved efficiency and focus in stakeholder identification and prioritization, enabling a more targeted and effective KOL engagement strategy and strengthening launch readiness in a complex rare disease landscape.
150+
Opinion Leaders
Identified across specialties
~40
Opinion Leaders
Engaged within 6 months
4+
Specialties Engaged
Across the care landscape
Our Perspectives on Advertising
2026 Oncology Market Access Trends
Implications of the IRA’s Maximum Fair Price (MFP) Negotiations
340B Drug Discount Program
Let’s Plan Your Next Pharmaceutical Commercial Breakthrough
At BGBx, we deliver breakthrough commercial solutions by bringing structure to stakeholder complexity, identifying and prioritizing the right experts to support focused engagement and effective launch planning.
